Chelsea blindsided again on Northera plan; shares plunge
This article was originally published in Scrip
Investors' confidence in Chelsea Therapeutics' ability to read the US FDA is waning, with shares of the firm tumbling as low as 52% on 3 July after the agency for the second time in recent months expressed doubt about how the company is going about providing efficacy and safety data for Northera (droxidopa) – declaring the company's latest proposal insufficient, making the drug's path to approval much more complex.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.